Subtopic Deep Dive
Cancer-Associated Myositis
Research Guide
What is Cancer-Associated Myositis?
Cancer-associated myositis refers to inflammatory myopathies, particularly dermatomyositis and polymyositis, occurring as paraneoplastic syndromes linked to underlying malignancies.
Anti-TIF1-γ and anti-NXP2 antibodies strongly associate with cancer in dermatomyositis patients (Fiorentino et al., 2013, 385 citations). Myositis-specific autoantibodies aid diagnosis and predict cancer risk (Betteridge and McHugh, 2015, 1019 citations; Chinoy et al., 2007, 338 citations). Over 20 papers in the provided list highlight epidemiological and serological links.
Why It Matters
Cancer-associated myositis drives screening protocols; patients with anti-TIF1-γ antibodies require age- and risk-appropriate cancer surveillance, improving malignancy detection rates (Fiorentino et al., 2013). Chinoy et al. (2007) showed myositis autoantibody testing predicts cancer-associated myositis, guiding oncologic interventions that enhance survival. Pelosof and Gerber (2010, 754 citations) outline paraneoplastic syndrome diagnosis, applied in myositis to reduce occult cancer mortality.
Key Research Challenges
Antibody Specificity Variability
Anti-TIF1-γ predicts cancer in dermatomyositis but shows geographic and age variations (Fiorentino et al., 2013). Betteridge and McHugh (2015) note myositis-specific autoantibodies vary in sensitivity for paraneoplastic cases. Standardization across populations remains unresolved.
Optimal Screening Protocols
No consensus exists on cancer screening intensity for myositis patients despite high malignancy risk (Chinoy et al., 2007). Pelosof and Gerber (2010) describe general paraneoplastic approaches but lack myositis-specific guidelines. Cost-effectiveness data are limited.
Paraneoplastic Mechanism Elucidation
Tumor-myositis links involve autoantibodies targeting nuclear proteins, yet causal pathways are unclear (Fiorentino et al., 2013). Hamaguchi et al. (2013, 386 citations) highlight anti-ARS antibody heterogeneity but not cancer mechanisms. Animal models are scarce.
Essential Papers
Myositis‐specific autoantibodies: an important tool to support diagnosis of myositis
Zoë Betteridge, NJ McHugh · 2015 · Journal of Internal Medicine · 1.0K citations
Abstract The idiopathic inflammatory myopathies are characterized by muscle weakness, skin disease and internal organ involvement. Autoimmunity is known to have a role in myositis pathogenesis, and...
Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
Lorraine Pelosof, David E. Gerber · 2010 · Mayo Clinic Proceedings · 754 citations
Natural history of Hodgkin's disease as related to its pathologic picture
Robert J. Lukes, James J. Butler, Ethel B. Hicks · 1966 · Cancer · 503 citations
This paper evaluates the significance of the clinical stages and histologic features of Hodgkin's disease in 377 U. S. Army cases from World War II with a 15- to 18-year follow-up. From this study ...
Common and Distinct Clinical Features in Adult Patients with Anti-Aminoacyl-tRNA Synthetase Antibodies: Heterogeneity within the Syndrome
Yasuhito Hamaguchi, Manabu Fujimoto, Takashi Matsushita et al. · 2013 · PLoS ONE · 386 citations
Patients with anti-ARS Abs are relatively homogeneous. However, the distribution and timing of myositis, ILD, and rashes differ among patients with individual anti-ARS Abs. Thus, identification of ...
Most Patients With Cancer‐Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP‐2 or Transcription Intermediary Factor 1γ
David Fiorentino, Leland W.K. Chung, Lisa Christopher‐Stine et al. · 2013 · Arthritis & Rheumatism · 385 citations
Objective Since dermatomyositis (DM) is associated with an increased risk of malignancy, accurate identification of patients likely to harbor cancers is important. Using immunoprecipitations from r...
The Association of Cancer and the Nephrotic Syndrome
John C. Lee, H. YAMAUCHI, JAMES HOPPER · 1966 · Annals of Internal Medicine · 380 citations
Article1 January 1966The Association of Cancer and the Nephrotic SyndromeJOHN C. LEE, M.D., H. YAMAUCHI, M.D., JAMES HOPPER JR., M.D.JOHN C. LEE, M.D., H. YAMAUCHI, M.D., JAMES HOPPER JR., M.D.Auth...
The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis
Hector Chinoy, Noreen Fertig, Carmine V. Oddis et al. · 2007 · Annals of the Rheumatic Diseases · 338 citations
Reading Guide
Foundational Papers
Read Pelosof and Gerber (2010, 754 citations) first for paraneoplastic framework, then Fiorentino et al. (2013, 385 citations) for myositis-specific antibodies, and Chinoy et al. (2007, 338 citations) for diagnostic utility—these establish core epidemiology and serology.
Recent Advances
Study Betteridge and McHugh (2015, 1019 citations) for updated autoantibody tools and Hamaguchi et al. (2013, 386 citations) for anti-ARS heterogeneity in cancer contexts.
Core Methods
Core techniques include immunoprecipitation for myositis autoantibodies (Fiorentino et al., 2013; Betteridge and McHugh, 2015), clinical serology panels (Chinoy et al., 2007), and risk stratification via antibody profiles (Hamaguchi et al., 2013).
How PapersFlow Helps You Research Cancer-Associated Myositis
Discover & Search
PapersFlow's Research Agent uses searchPapers with 'cancer-associated myositis anti-TIF1' to retrieve Fiorentino et al. (2013), then citationGraph reveals 385 citing papers on antibody-cancer links, and findSimilarPapers expands to Chinoy et al. (2007) for diagnostic utility.
Analyze & Verify
Analysis Agent applies readPaperContent to extract anti-TIF1-γ prevalence from Fiorentino et al. (2013), verifies claims via verifyResponse (CoVe) against Betteridge and McHugh (2015), and runPythonAnalysis computes meta-analysis odds ratios from citation data with GRADE grading for high-confidence serological predictions.
Synthesize & Write
Synthesis Agent detects gaps in screening protocols post-Chinoy et al. (2007), flags contradictions between anti-ARS homogeneity (Hamaguchi et al., 2013) and cancer specificity; Writing Agent uses latexEditText for review drafting, latexSyncCitations for 10+ papers, and latexCompile for publication-ready output with exportMermaid timelines of myositis-cancer associations.
Use Cases
"Extract survival data from cancer-associated myositis papers and plot Kaplan-Meier curves."
Research Agent → searchPapers('cancer myositis survival') → Analysis Agent → readPaperContent(Fiorentino 2013) → runPythonAnalysis(pandas survival analysis, matplotlib plots) → researcher gets CSV data and GRADE-verified curves.
"Draft LaTeX review on anti-TIF1-γ screening guidelines."
Synthesis Agent → gap detection(Chinoy 2007, Betteridge 2015) → Writing Agent → latexGenerateFigure(surveillance flowchart) → latexSyncCitations → latexCompile → researcher gets compiled PDF with synced references.
"Find GitHub code for myositis autoantibody prediction models."
Research Agent → searchPapers('myositis autoantibody model') → Code Discovery → paperExtractUrls(Betteridge 2015) → paperFindGithubRepo → githubRepoInspect → researcher gets runnable Jupyter notebooks for antibody risk calculators.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ cancer myositis papers) → citationGraph → DeepScan(7-step verifyResponse/CoVe on abstracts) → structured report on antibody prevalences. Theorizer generates hypotheses on anti-TIF1-γ mechanisms from Fiorentino et al. (2013) and Hamaguchi et al. (2013), outputting Mermaid causal diagrams. DeepScan analyzes Chinoy et al. (2007) with runPythonAnalysis for diagnostic odds ratios and GRADE evidence synthesis.
Frequently Asked Questions
What defines cancer-associated myositis?
Cancer-associated myositis is dermatomyositis or polymyositis linked to malignancy, marked by autoantibodies like anti-TIF1-γ and anti-NXP2 (Fiorentino et al., 2013). It differs from idiopathic forms by paraneoplastic onset and tumor regression post-cancer therapy.
What are key diagnostic methods?
Myositis-specific autoantibody panels detect anti-TIF1-γ for cancer risk (Betteridge and McHugh, 2015; Chinoy et al., 2007). Immunoprecipitation from cell lysates identifies predictors (Fiorentino et al., 2013).
What are seminal papers?
Fiorentino et al. (2013, 385 citations) links anti-NXP2/TIF1-γ to cancer-dermatomyositis. Chinoy et al. (2007, 338 citations) validates autoantibodies for cancer prediction. Betteridge and McHugh (2015, 1019 citations) reviews diagnostic tools.
What open problems persist?
Unclear paraneoplastic mechanisms despite antibody associations (Fiorentino et al., 2013). Lack of standardized screening reduces early detection. Heterogeneity in anti-ARS effects on cancer risk needs clarification (Hamaguchi et al., 2013).
Research Inflammatory Myopathies and Dermatomyositis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cancer-Associated Myositis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers